• Yoshifumi Baba, Hideo Baba, Sachiko Yamamoto, Hideaki Shimada, Tomotaka Shibata, Tatsuya Miyazaki, Takaki Yoshikawa, Yasuaki Nakajima, Yasushi Tsuji, Mototsugu Shimokawa, Yuko Kitagawa, and Keisuke Aiba.
• Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Chuo-ku, Kumamoto, Japan.
• Dis. Esophagus. 2017 Feb 1; 30 (2): 1-7.

AbstractChemotherapy is an indispensable therapeutic approach for esophageal cancer. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, the current state of CINV in patients with esophageal cancer remains unclear. This multicenter prospective observational study analyzed data for 192 patents with esophageal cancer who underwent moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). The patients recorded their CINV incidence and severity daily for 7 days after receiving chemotherapy, using visual analog scales (VAS). Of the 192 patients, 181 received HEC including cisplatin, and 11 patients received MEC including nedaplatin. Approximately 81% of HEC and 82% of MEC patients received antiemetic therapy in compliance with guidelines. Although CINV was controlled relatively well in the early phase (days 1-4), it was not fully controlled in late phase (days 5-7) for both the HEC and MEC groups. Female sex was a major risk factor for delayed vomiting (P=0.034). Multivariate logistic regression analysis for VAS revealed that motion sickness, age, and use of other antiemetics were risk factors for delayed nausea. Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed CINV in both HEC and MEC patients. Identification of individual risk factors, such as female sex, will help develop personalized treatments for CINV. In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC.© 2016 International Society for Diseases of the Esophagus.

38 keywords...

hide…